Pacira BioSciences Revenue vs. Net Income
| PCRX Stock | USD 19.30 0.14 0.73% |
Total Revenue | First Reported 2008-12-31 | Previous Quarter 181.1 M | Current Value 179.5 M | Quarterly Volatility 61.9 M |
For Pacira BioSciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pacira BioSciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pacira BioSciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pacira BioSciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pacira BioSciences over time as well as its relative position and ranking within its peers.
Pacira BioSciences' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Pacira BioSciences Revenue Breakdown by Earning Segment
By analyzing Pacira BioSciences' earnings estimates, investors can diagnose different trends across Pacira BioSciences' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira BioSciences. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.47 | Revenue Per Share | Quarterly Revenue Growth 0.065 | Return On Assets |
The market value of Pacira BioSciences is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Pacira BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira BioSciences' market value can be influenced by many factors that don't directly affect Pacira BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pacira BioSciences Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pacira BioSciences's current stock value. Our valuation model uses many indicators to compare Pacira BioSciences value to that of its competitors to determine the firm's financial worth. Pacira BioSciences is regarded second in revenue category among its peers. It is regarded fifth in net income category among its peers . At this time, Pacira BioSciences' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pacira BioSciences' earnings, one of the primary drivers of an investment's value.Pacira Revenue vs. Competition
Pacira BioSciences is regarded second in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 2.11 Billion. Pacira BioSciences totals roughly 700.97 Million in revenue claiming about 33% of equities under Health Care industry.
Pacira Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Pacira BioSciences |
| = | 700.97 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Pacira BioSciences |
| = | (99.56 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Pacira Net Income Comparison
Pacira BioSciences is currently under evaluation in net income category among its peers.
Pacira BioSciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pacira BioSciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pacira BioSciences will eventually generate negative long term returns. The profitability progress is the general direction of Pacira BioSciences' change in net profit over the period of time. It can combine multiple indicators of Pacira BioSciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 394.4 K | 414.2 K | |
| Operating Income | -84.4 M | -80.2 M | |
| Income Before Tax | -72.6 M | -68.9 M | |
| Total Other Income Expense Net | 9.2 M | 9.7 M | |
| Net Loss | -114.5 M | -108.8 M | |
| Income Tax Expense | 32.8 M | 34.4 M | |
| Net Loss | -114.5 M | -108.8 M | |
| Non Operating Income Net Other | -2 M | -1.9 M | |
| Net Income Applicable To Common Shares | 18.3 M | 19.2 M | |
| Interest Income | 22.6 M | 23.8 M | |
| Net Interest Income | 2.8 M | 2.9 M | |
| Change To Netincome | 66.2 M | 69.5 M | |
| Net Loss | (1.94) | (2.03) | |
| Income Quality | (2.19) | (2.30) | |
| Net Income Per E B T | 1.42 | 1.17 |
Pacira Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pacira BioSciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pacira BioSciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pacira BioSciences' important profitability drivers and their relationship over time.
Pacira BioSciences Earnings Estimation Breakdown
The calculation of Pacira BioSciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Pacira BioSciences is estimated to be 0.7325 with the future projection ranging from a low of 0.62 to a high of 0.85. Please be aware that this consensus of annual earnings estimates for Pacira BioSciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.62 Lowest | Expected EPS | 0.85 Highest |
Pacira BioSciences Earnings Projection Consensus
Suppose the current estimates of Pacira BioSciences' value are higher than the current market price of the Pacira BioSciences stock. In this case, investors may conclude that Pacira BioSciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pacira BioSciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 7 | 81.97% | 0.0 | 0.7325 | 0.47 |
Pacira BioSciences Earnings per Share Projection vs Actual
Actual Earning per Share of Pacira BioSciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pacira BioSciences predict the company's earnings will be in the future. The higher the earnings per share of Pacira BioSciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Pacira BioSciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Pacira BioSciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pacira BioSciences should always be considered in relation to other companies to make a more educated investment decision.Pacira Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Pacira BioSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | 0.65 | 0.7 | 0.05 | 7 | ||
2025-08-05 | 2025-06-30 | 0.72 | -0.11 | -0.83 | 115 | ||
2025-05-05 | 2025-03-31 | 0.5971 | 0.62 | 0.0229 | 3 | ||
2025-02-26 | 2024-12-31 | 0.8303 | 0.91 | 0.0797 | 9 | ||
2024-11-06 | 2024-09-30 | 0.7 | 0.79 | 0.09 | 12 | ||
2024-07-30 | 2024-06-30 | 0.7 | 0.89 | 0.19 | 27 | ||
2024-05-07 | 2024-03-31 | 0.62 | 0.62 | 0.0 | 0 | ||
2024-02-29 | 2023-12-31 | 0.88 | 0.89 | 0.01 | 1 | ||
2023-11-02 | 2023-09-30 | 0.78 | 0.72 | -0.06 | 7 | ||
2023-08-02 | 2023-06-30 | 0.76 | 0.78 | 0.02 | 2 | ||
2023-05-03 | 2023-03-31 | 0.62 | 0.53 | -0.09 | 14 | ||
2023-02-28 | 2022-12-31 | 0.83 | 0.8 | -0.03 | 3 | ||
2022-11-03 | 2022-09-30 | 0.76 | 0.64 | -0.12 | 15 | ||
2022-08-03 | 2022-06-30 | 0.85 | 0.51 | -0.34 | 40 | ||
2022-05-04 | 2022-03-31 | 0.83 | 0.64 | -0.19 | 22 | ||
2022-02-24 | 2021-12-31 | 0.9 | 0.97 | 0.07 | 7 | ||
2021-11-03 | 2021-09-30 | 0.65 | 0.72 | 0.07 | 10 | ||
2021-08-03 | 2021-06-30 | 0.74 | 0.77 | 0.03 | 4 | ||
2021-05-04 | 2021-03-31 | 0.64 | 0.53 | -0.11 | 17 | ||
2021-02-25 | 2020-12-31 | 0.81 | 0.87 | 0.06 | 7 | ||
2020-10-29 | 2020-09-30 | 0.62 | 0.68 | 0.06 | 9 | ||
2020-08-06 | 2020-06-30 | 0.11 | 0.12 | 0.01 | 9 | ||
2020-05-07 | 2020-03-31 | 0.3 | 0.53 | 0.23 | 76 | ||
2020-02-20 | 2019-12-31 | 0.44 | 0.56 | 0.12 | 27 | ||
2019-11-07 | 2019-09-30 | 0.33 | 0.48 | 0.15 | 45 | ||
2019-08-08 | 2019-06-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2019-05-02 | 2019-03-31 | 0.26 | 0.22 | -0.04 | 15 | ||
2019-02-28 | 2018-12-31 | 0.28 | 0.47 | 0.19 | 67 | ||
2018-11-01 | 2018-09-30 | 0.08 | 0.31 | 0.23 | 287 | ||
2018-08-02 | 2018-06-30 | 0.07 | 0.24 | 0.17 | 242 | ||
2018-05-03 | 2018-03-31 | 0.02 | 0.02 | 0.0 | 0 | ||
2018-02-28 | 2017-12-31 | 0.1 | 0.38 | 0.28 | 280 | ||
2017-11-08 | 2017-09-30 | -0.06 | 0.11 | 0.17 | 283 | ||
2017-08-02 | 2017-06-30 | -0.05 | -0.11 | -0.06 | 120 | ||
2017-05-04 | 2017-03-31 | -0.04 | -0.19 | -0.15 | 375 | ||
2017-03-01 | 2016-12-31 | 0.01 | 0.09 | 0.08 | 800 | ||
2016-11-02 | 2016-09-30 | -0.02 | 0.2 | 0.22 | 1100 | ||
2016-08-04 | 2016-06-30 | 0.03 | 0.19 | 0.16 | 533 | ||
2016-05-02 | 2016-03-31 | 0.08 | 0.14 | 0.06 | 75 | ||
2016-02-25 | 2015-12-31 | 0.27 | 0.2 | -0.07 | 25 | ||
2015-10-27 | 2015-09-30 | 0.15 | 0.32 | 0.17 | 113 | ||
2015-07-30 | 2015-06-30 | 0.23 | 0.2 | -0.03 | 13 | ||
2015-04-30 | 2015-03-31 | 0.2 | 0.23 | 0.03 | 15 | ||
2015-02-24 | 2014-12-31 | 0.27 | 0.35 | 0.08 | 29 | ||
2014-10-30 | 2014-09-30 | 0.1 | 0.14 | 0.04 | 40 | ||
2014-07-31 | 2014-06-30 | -0.21 | -0.14 | 0.07 | 33 | ||
2014-05-01 | 2014-03-31 | -0.32 | -0.34 | -0.02 | 6 | ||
2014-02-25 | 2013-12-31 | -0.27 | -0.36 | -0.09 | 33 | ||
2013-10-31 | 2013-09-30 | -0.35 | -0.44 | -0.09 | 25 | ||
2013-08-06 | 2013-06-30 | -0.43 | -0.42 | 0.01 | 2 | ||
2013-05-08 | 2013-03-31 | -0.41 | -0.71 | -0.3 | 73 | ||
2013-03-07 | 2012-12-31 | -0.42 | -0.5 | -0.08 | 19 | ||
2012-11-01 | 2012-09-30 | -0.44 | -0.49 | -0.05 | 11 | ||
2012-08-09 | 2012-06-30 | -0.43 | -0.23 | 0.2 | 46 | ||
2012-05-09 | 2012-03-31 | -0.39 | -0.47 | -0.08 | 20 | ||
2012-03-27 | 2011-12-31 | -0.54 | -0.58 | -0.04 | 7 | ||
2011-10-31 | 2011-09-30 | -0.59 | -0.55 | 0.04 | 6 | ||
2011-08-11 | 2011-06-30 | -0.58 | -0.51 | 0.07 | 12 | ||
2011-05-11 | 2011-03-31 | -0.53 | -0.98 | -0.45 | 84 |
Use Pacira BioSciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pacira BioSciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pacira BioSciences will appreciate offsetting losses from the drop in the long position's value.Pacira BioSciences Pair Trading
Pacira BioSciences Pair Trading Analysis
The ability to find closely correlated positions to Pacira BioSciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pacira BioSciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pacira BioSciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pacira BioSciences to buy it.
The correlation of Pacira BioSciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pacira BioSciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pacira BioSciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pacira BioSciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pacira BioSciences position
In addition to having Pacira BioSciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences' price analysis, check to measure Pacira BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences is operating at the current time. Most of Pacira BioSciences' value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences' price. Additionally, you may evaluate how the addition of Pacira BioSciences to your portfolios can decrease your overall portfolio volatility.